Semaglutide in the Real World: Attitudes of the Population
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- De Luca, L.; Bilato, C.; Navazio, A.; Corda, M.; Milli, M.; Scicchitano, P.; Di Marco, M.; Riccio, C.; Geraci, G.; Iacovoni, A.; et al. ANMCO statement: Semaglutide in the cardio-nephro-metabolic continuum. Eur. Heart J. Suppl. 2025, 27, v247–v255. [Google Scholar] [CrossRef]
- Sorli, C.; Harashima, S.I.; Tsoukas, G.M.; Unger, J.; Karsbøl, J.D.; Hansen, T.; Bain, S.C. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet. Diabetes Endocrinol. 2017, 5, 251–260. [Google Scholar] [CrossRef] [PubMed]
- Frías, J.P.; Auerbach, P.; Bajaj, H.S.; Fukushima, Y.; Lingvay, I.; Macura, S.; Søndergaard, A.L.; Tankova, T.I.; Tentolouris, N.; Buse, J.B. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): A double-blind, randomised, phase 3B trial. The lancet. Diabetes Endocrinol. 2021, 9, 563–574. [Google Scholar] [CrossRef] [PubMed]
- Won, H.; Cho, J.Y.; Lee, S. Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: Focusing on early phase clinical trials. Transl. Clin. Pharmacol. 2025, 33, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Aroda, V.R.; Ahmann, A.; Cariou, B.; Chow, F.; Davies, M.J.; Jódar, E.; Mehta, R.; Woo, V.; Lingvay, I. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019, 45, 409–418. [Google Scholar] [CrossRef]
- Pratley, R.E.; Aroda, V.R.; Lingvay, I.; Lüdemann, J.; Andreassen, C.; Navarria, A.; Viljoen, A.; SUSTAIN 7 Investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018, 6, 275–286. [Google Scholar] [CrossRef] [PubMed]
- Pratley, R.E.; Tuttle, K.R.; Rossing, P.; Rasmussen, S.; Perkovic, V.; Nielsen, O.W.; Mann, J.F.E.; MacIsaac, R.J.; Kosiborod, M.N.; Kamenov, Z.; et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J. Am. Coll. Cardiol. 2024, 84, 1615–1628. [Google Scholar] [CrossRef]
- Amaro, A.; Sugimoto, D.; Wharton, S. Efficacy and safety of semaglutide for weight management: Evidence from the STEP program. Postgrad. Med. 2022, 134 (Suppl. S1), 5–17. [Google Scholar] [CrossRef]
- Garvey, W.T.; Batterham, R.L.; Bhatta, M.; Buscemi, S.; Christensen, L.N.; Frias, J.P.; Jódar, E.; Kandler, K.; Rigas, G.; Wadden, T.A.; et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat. Med. 2022, 28, 2083–2091. [Google Scholar] [CrossRef]
- Colhoun, H.M.; Lingvay, I.; Brown, P.M.; Deanfield, J.; Brown-Frandsen, K.; Kahn, S.E.; Plutzky, J.; Node, K.; Parkhomenko, A.; Rydén, L.; et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 2024, 30, 2058–2066. [Google Scholar] [CrossRef]
- Ghusn, W.; De la Rosa, A.; Sacoto, D.; Cifuentes, L.; Campos, A.; Feris, F.; Hurtado, M.D.; Acosta, A. Weight Loss Outcomes Associated with Semaglutide Treatment for Patients with Overweight or Obesity. JAMA Netw. Open 2022, 5, e2231982. [Google Scholar] [CrossRef] [PubMed]
- Ryan, D.H.; Lingvay, I.; Deanfield, J.; Kahn, S.E.; Barros, E.; Burguera, B.; Colhoun, H.M.; Cercato, C.; Dicker, D.; Horn, D.B.; et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat. Med. 2024, 30, 2049–2057. [Google Scholar] [CrossRef] [PubMed]
- Tan, H.C.; Dampil, O.A.; Marquez, M.M. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J. ASEAN Fed. Endocr. Soc. 2022, 37, 65–72. [Google Scholar] [CrossRef] [PubMed]
- Ashraf, A.R.; Mackey, T.K.; Vida, R.G.; Kulcsar, G.; Schmidt, J.; Balázs, O.; Domián, B.M.; Li, J.; Csákó, I.; Fittler, A. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J. Med. Internet Res. 2024, 26, e65440. [Google Scholar] [CrossRef]
- Ryan, N.; Savulescu, J. The Ethics of Ozempic and Wegovy. J. Med. Ethics 2025, jme-2024-110374. [Google Scholar] [CrossRef]
- Raubenheimer, J.E.; Myburgh, P.H.; Bhagavathula, A.S. Sweetening the deal: An infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface. BMC Glob. Public Health 2024, 2, 63. [Google Scholar] [CrossRef]
- Tselebis, A.; Zabuliene, L.; Ilias, I. Is global interest in fasting, intermittent fasting and the liver shifting? World J. Hepatol. 2025, 17, 101910. [Google Scholar] [CrossRef]
- Nikolis, A.; Enright, K.M.; Fabi, S.G.; Somenek, M.; Cartier, H.; Avelar, L.; Franco, J.; Haddad, A.; Angelo-Khattar, M.; Huang, J.; et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. J. Cosmet. Dermatol. 2025, 24, e70094. [Google Scholar] [CrossRef]
- Castellana, E.; Chiappetta, M.R. Semaglutide: A gendered phenomenon-women’s increased vulnerability to adverse drug reactions in the global weight loss trend. Ther. Adv. Drug Saf. 2025, 16, 20420986251332737. [Google Scholar] [CrossRef]
- Reitzinger, S.; Czypionka, T. Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective. Sci. Rep. 2025, 15, 12959. [Google Scholar] [CrossRef]
- McEwan, P.; Bog, M.; Faurby, M.; Foos, V.; Lingvay, I.; Lübker, C.; Miller, R.; Toliver, J.C.; Yeates, F.; Lincoff, A.M. Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. J. Med. Econ. 2025, 28, 268–278. [Google Scholar] [CrossRef]
- Hwang, J.H.; Laiteerapong, N.; Huang, E.S.; Kim, D.D. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum 2025, 6, e245586. [Google Scholar] [CrossRef]
- Oshman, L.; Kirch, M.; Solway, E.; Singer, D.C.; Malani, P.N.; Roberts, J.S.; Kullgren, J.T.; Griauzde, D.H. Older Adults’ Views on Insurance Coverage for Weight Management Medications. JAMA Netw. Open 2025, 8, e252008. [Google Scholar] [CrossRef] [PubMed]
- Raičević, B.B.; Belančić, A.; Mirković, N.; Janković, S.M. Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs. Pharmacol. Res. Perspect. 2025, 13, e70080. [Google Scholar] [CrossRef] [PubMed]
- Shareef, L.G.; Khalid, S.S.; Raheem, M.F.; Al-Hussainy, A.F.; Al-Khayyat, N.S.; Al Arajy, A.Z.; Noori, M.M.; Qasim, M.A.; Jasim, H.H. Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study. Cureus 2024, 16, e71569. [Google Scholar] [CrossRef] [PubMed]
- Agency for Medicinal Products and Medical Devices. Medicinal Products Database. Ozempic Summary of Product Characteristics. Available online: https://www.ema.europa.eu/hr/documents/product-information/ozempic-epar-product-information_hr.pdf (accessed on 21 May 2025).
- Peyyety, V.; Jankowski, M.; Apte, S.; Sindelar, J.; Elrajabi, R.; Chang, T.; Sonneville, K.; Vajravelu, M.E. Youth Perspectives on the Use of Medications for Weight Loss. J. Adolesc. Health 2025, 77, 262–268. [Google Scholar] [CrossRef]
- Sorensen, M.S.; Pottegard, A.; Andersen, N.E.; Thomsen, R.W.; Lundby, C. Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects. Diabetes Obes. Metab. 2025, 27, 2214–2222. [Google Scholar] [CrossRef]
- Yang, Y.; He, L.; Han, S.; Yang, N.; Liu, Y.; Wang, X.; Li, Z.; Ping, F.; Xu, L.; Li, W.; et al. Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis. J. Diabetes 2025, 17, e70063. [Google Scholar] [CrossRef]
- Campos-Rivera, P.A.; Alfaro-Ponce, B.; Ramirez-Perez, M.; Bernal-Serrano, D.; Contreras-Loya, D.; Wirtz, V.J. Quality of information and social norms in Spanish-speaking TikTok videos as levers of commercial practices: The case of semaglutide. Soc. Sci. Med. 2025, 366, 117646. [Google Scholar] [CrossRef]
- Alvarez-Mon, M.A.; Llavero-Valero, M.; Asunsolo Del Barco, A.; Zaragozá, C.; Ortega, M.A.; Lahera, G.; Quintero, J.; Alvarez-Mon, M. Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter. J. Med. Internet Res. 2021, 23, e24336. [Google Scholar] [CrossRef]
- Thomsen, R.W.; Mailhac, A.; Lohde, J.B.; Pottegard, A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes. Metab. 2025, 27 (Suppl. S2), 66–88. [Google Scholar] [CrossRef]
- Ho, R.Y.; Regelman, H.; Ma, A.; Lee, S.Y.; Sandhu, S.; Shapiro, S.; Lewis, J.; Tsutaoka, B.; Apollonio, D.E. Changes in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Exposures Following Recent Demand for Weight Management: A Retrospective Review of California Poison Control System Data. J. Pharm. Technol. 2025, 41, 165–173. [Google Scholar] [CrossRef]
- Lakhani, M.; Kwan, A.T.; Mihalache, A.; Popovic, M.M.; Nanji, K.; Xie, J.S.; Feo, A.; Rabinovitch, D.; Shor, R.; Sadda, S.; et al. Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries. Am. J. Ophthalmol. 2025, 277, 148–168. [Google Scholar] [CrossRef]
- Zhao, T.; Zheng, L.; Feng, Y.; Lao, M.; Huang, Y.; Wu, G. Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting. BMC Ophthalmol. 2025, 25, 248. [Google Scholar] [CrossRef] [PubMed]
- Massy, M.; Marti, S.; Hammer, H.; Hoepner, R. Increased vision impairment reports linked to semaglutide: Analysis of FDA adverse event data. BMC Med. 2025, 23, 203. [Google Scholar] [CrossRef] [PubMed]
- Bloomgarden, Z.T. Semaglutide and the Retina. J. Diabetes 2025, 17, e70085. [Google Scholar] [CrossRef] [PubMed]
- Lu, W.; Wang, S.; Tang, H.; Yuan, T.; Zuo, W.; Liu, Y. Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database. Eur. Psychiatry 2025, 68, e20. [Google Scholar] [CrossRef]
- Yeung, A.W.K.; Hammerle, F.P.; Behrens, S.; Matin, M.; Mickael, M.E.; Litvinova, O.; Parvanov, E.D.; Kletecka-Pulker, M.; Atanasov, A.G. Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos. JMIR Infodemiology 2025, 5, e59767. [Google Scholar] [CrossRef]
- Callaghan, T.; Motta, M.; Stein, M.; Goidel, K. The prevalence and consequences of support for off-label Ozempic prescriptions. Health Econ. Policy Law 2025, 7, 1–14. [Google Scholar] [CrossRef]
- Dicker, D.; Tamir, O.; Lieberman-Segal, G.; Eldor, R.; Accos-Carmel, M.; Kolobov, T.; Karasik, A. Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel. Isr. Med. Assoc. J. IMAJ 2023, 25, 664. [Google Scholar] [PubMed]
- Gatto, L.; Biccire, F.G.; Lentini, A.E.; Scalia, L.; Prati, F. From the SELECT study to SOUL: Different administration methods of semaglutide but same efficacy? Eur. Heart J. Suppl. 2025, 27, iii98–iii101. [Google Scholar] [CrossRef]
- Karedath, J.; Nall, S.; Kaur, M.; Lokhandwala, A.; Aqel, Y.H.; Abusal, A.M.; Wei, C.R.; Allahwala, D. Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Cureus 2025, 17, e82497. [Google Scholar] [CrossRef] [PubMed]
- Abutaima, R.; Barakat, M.; Sawan, H.M.; Al Omari, S.M.; Mhaidat, N.M. Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study. PLoS ONE 2024, 19, e0314407. [Google Scholar] [CrossRef] [PubMed]
- Algarni, M.A.; Algarni, A.A.M.; Alqarni, W.A.; Alqassim, A.Y. Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study. Cureus 2023, 15, e42875. [Google Scholar] [CrossRef]
- McVay, M.A.; Moore, W.S.; Wilkins, F.L.; Jackson, J.R.; Robinson, M.D. Patient perspectives on incretin-based weight loss medications and relationship with demographic factors. Obes. Sci. Pract. 2024, 10, e783. [Google Scholar] [CrossRef]
Characteristic | N (%) |
---|---|
Total | 290 (100.0%) |
Sex | |
Women | 243 (83.8%) |
Men | 47 (16.2%) |
Age (years) | |
18–25 | 53 (18.3%) |
26–35 | 67 (23.1%) |
36–45 | 42 (14.5%) |
46–55 | 56 (19.3%) |
56–65 | 49 (16.9%) |
65+ | 23 (7.9%) |
Highest level of education achieved | |
Postgraduate scientific master’s studies or postgraduate university (doctoral) studies | 19 (6.6%) |
University graduate studies; specialist graduate professional studies; postgraduate specialist studies | 154 (53.1%) |
University undergraduate studies; professional undergraduate studies | 44 (15.2%) |
General secondary education (gymnasium); four-year and five-year vocational secondary education | 63 (21.7%) |
Three-year vocational education | 7 (2.4%) |
Primary education or less | 3 (1.0%) |
Family member working in healthcare | |
Yes | 94 (32.4%) |
No | 196 (67.6%) |
Has type 2 diabetes mellitus | |
Yes | 11 (3.8%) |
No | 279 (96.2%) |
Men (N = 47) | Women (N = 243) | p-Value | Total (N = 290) | |
---|---|---|---|---|
How often do you think about losing weight? | ||||
Very often | 5 (10.6%) | 28 (11.5%) | 0.016 | 33 (11.4%) |
Often | 5 (10.6%) | 69 (28.4%) | 74 (25.5%) | |
Sometimes | 22 (46.8%) | 107 (44.0%) | 129 (44.5%) | |
Never | 15 (31.8%) | 39 (16.0%) | 54 (18.6%) | |
Do you know that Ozempic® is used for weight loss, although it was developed for the treatment of type 2 diabetes mellitus? | ||||
Yes | 35 (74.5%) | 188 (77.4%) | 0.667 | 223 (76.9%) |
No | 12 (25.5%) | 55 (22.6%) | 67 (23.1%) | |
Which of the following have you used for weight loss? | ||||
Diets | 7 (14.9%) | 103 (42.4%) | <0.001 | 110 (37.9%) |
Dietary supplements | 7 (14.9%) | 29 (11.9%) | 0.574 | 36 (12.4%) |
Medications | 0(0.0%) | 4 (1.6%) | 0.491 | |
Nothing | 34 (72.3%) | 122 (50.2%) | 0.005 | 156 (53.8%) |
Family Member Health Care Worker | Yes (N = 94) | No (N = 196) | p-Value | Total (N = 290) |
---|---|---|---|---|
What is the route of administration of Ozempic®? | ||||
Subcutaneous | 64 (68.1%) | 107 (54.6%) | 0.025 | 171 (59.4%) |
Intravenous | 1 (1.1%) | 14 (7.1%) | 15 (5.2%) | |
Per os | 28 (29.8%) | 74 (37.8%) | 102 (35.4%) | |
Did you or someone you know take Ozempic® for weight loss? | ||||
I took it and I know someone who took it | 0(0.0%) | 1 (0.5%) | 0.407 | 1 (0.3%) |
Someone I know took it | 26 (27.7%) | 41 (20.9%) | 67 (23.1%) | |
No | 68 (72.3%) | 154 (78.6%) | 222 (76.6%) |
Family Member Health Care Worker/Adverse Drug Reaction | Frequency of Adverse Reaction According to SmPC for Ozempic® [26] | Yes (N = 94) | No (N = 196) | p-Value | Total (N = 290) |
---|---|---|---|---|---|
I am not informed | - | 45 (47.9%) | 147 (75.0%) | <0.001 | 192 (66.2%) |
Nausea | ≥1/10 | 40 (42.5%) | 36 (18.4%) | <0.001 | 76 (26.2%) |
Gastrointestinal disturbances | ≥1/100 and <1/10 | 37 (39.4%) | 32 (46.4%) | <0.001 | 69 (23.8%) |
Acute pancreatitis | ≥1/1000 and <1/100 | 21 (10.7%) | 28 (29.8%) | <0.001 | 49 (16.6%) |
Anaphylaxis | ≥1/10 000 and <1/1000 | 13 (13.8%) | 10 (5.1%) | 0.010 | 23 (7.9%) |
Gastritis | ≥1/100 and <1/10 | 12 (12.8%) | 10 (5.1%) | 0.021 | 22 (7.6%) |
Increased heart rate | ≥1/1000 and <1/100 | 10 (10.6%) | 9 (4.6%) | 0.052 | 19 (6.6%) |
Cholelithiasis | ≥1/100 and <1/10 | 12 (12.8%) | 6 (3.1%) | 0.001 | 18 (6.2%) |
Thyroid cancer | not reported | 9 (9.6%) | 8 (4.1%) | 0.063 | 17 (5.9%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rušić, D.; Durdov, T.; Jadrijević, I.; Šešelja Perišin, A.; Leskur, D.; Božić, J.; Klusmeier, M.M.; Bukić, J. Semaglutide in the Real World: Attitudes of the Population. Pharmacy 2025, 13, 128. https://doi.org/10.3390/pharmacy13050128
Rušić D, Durdov T, Jadrijević I, Šešelja Perišin A, Leskur D, Božić J, Klusmeier MM, Bukić J. Semaglutide in the Real World: Attitudes of the Population. Pharmacy. 2025; 13(5):128. https://doi.org/10.3390/pharmacy13050128
Chicago/Turabian StyleRušić, Doris, Toni Durdov, Ivona Jadrijević, Ana Šešelja Perišin, Dario Leskur, Joško Božić, Mila Marie Klusmeier, and Josipa Bukić. 2025. "Semaglutide in the Real World: Attitudes of the Population" Pharmacy 13, no. 5: 128. https://doi.org/10.3390/pharmacy13050128
APA StyleRušić, D., Durdov, T., Jadrijević, I., Šešelja Perišin, A., Leskur, D., Božić, J., Klusmeier, M. M., & Bukić, J. (2025). Semaglutide in the Real World: Attitudes of the Population. Pharmacy, 13(5), 128. https://doi.org/10.3390/pharmacy13050128